Structure Therapeutics advances aleniglipron to Phase 3 with FDA clearance; $100M license fee extends cash runway to end-2028

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Aleniglipron demonstrated 16.3% placebo-adjusted weight loss at 44 weeks (180 mg dose) in March 2026 data; FDA provided positive end-of-Phase 2 feedback and the company is on track to initiate Phase 3 trials in Q3 2026.

  MD&A: Aleniglipron Phase 3 Readiness verify on EDGAR →
• high

  Company received $100 million upfront licensing fee in Q1 2026 for patents covering a different class of oral GLP-1 receptor agonists (not aleniglipron), strengthening the balance sheet without impacting the core program.

  MD&A: Licensing Fee verify on EDGAR →
• high

  Cash runway extended from 'at least 2027' to 'through end-2028' and now explicitly includes Phase 3 registrational program costs; cash balance increased to $1.46 billion (up $622 million year-over-year) following $702 million December 2025 follow-on offering and $100 million licensing fee.

  MD&A: Cash Runway & Liquidity verify on EDGAR →